Group 1: Trading Suspension and Resumption - Tianpu Co., Ltd. has completed the stock trading suspension verification work and will resume trading tomorrow [1] - Pinming Technology is planning a significant matter that may lead to a change in company control, resulting in stock suspension [1] Group 2: Share Buybacks and Equity Transfers - Shuo Beid has proposed to adjust the upper limit of the share buyback price from 19.50 yuan per share to 30.00 yuan per share [2] - Shareholder SCPE of Aidi Te intends to transfer 3% of its equity through an inquiry [2] Group 3: External Investments and Daily Operations - Maiwei Bio has signed an exclusive licensing agreement with Kalexo, potentially receiving up to 1 billion USD in upfront and milestone payments [3] - Xingye Technology has signed a strategic cooperation agreement with Suzhou Nengsida to jointly develop flexible electronic skin [4] - Anke Bio's investee company PA3-17 injection has been approved to enter a critical Phase II clinical trial, being the first targeted CD7 autologous CAR-T cell therapy product to receive clinical trial approval globally [4] - Xujiahui has adjusted the Shanghai Liubai urban renewal project, with a planned total investment of approximately 1.698 billion yuan and an estimated construction period of 30-36 months [4] - Heng Rui Pharmaceutical's application for a new indication of injection Rituximab for breast cancer patients has been accepted and included in the priority review; drug HRS-5635 injection has been listed as a proposed breakthrough therapy [4] - Changhua Group has received a designated development notification from a domestic car manufacturer, with a total lifecycle sales amount of approximately 280 million yuan, expected to gradually start mass production in Q1 2027 [4] - Lvtong Technology has signed a strategic cooperation framework agreement with a subsidiary of Greeenmei Holdings for collaboration [5] - Runjian Co., Ltd. plans to issue debt financing instruments not exceeding 6 billion yuan to meet funding needs for computing power and other business [6] - Zhifei Biological's innovative drug CA111 injection has been approved to conduct clinical trials in overweight or obese adult patients [7] - Huahai Pharmaceutical's subsidiary has received FDA approval to conduct Phase I clinical trials for injection HB0043 [8] - Seli Medical plans to increase investment in Wuhan Huajiyuan by 42.74 million yuan to advance the therapeutic antihypertensive vaccine (HJY-ATRQβ-001) project through various clinical trial phases [8] - Changchun Gaoxin's subsidiary Jin Sai Pharmaceutical has paid 32.7 million euros to obtain exclusive rights to three ALK products in mainland China [9] - Greeenmei has signed a memorandum of understanding with ASCEND ELEMENTS to explore battery recycling and material cooperation in Europe [10]